Expression of p63 protein in pulmonary adenocarcinomas as factor of poor prognosis

Aim. To study the spectrum of cellular molecular-biological markers and identify those of them that can be used as prognostic factors for the clinical course of pulmonary adenocarcinoma. Material and Methods. In the given work archive material of 129 patients with confirmed diagnosis of pulmonary adenocarcinoma was used. In the work, histological, immunohistochemical, molecular-genetic and statistical methods were used. Results. In 29 cases (47.5%) of pulmonary adenocarcinoma, focal cytoplasmic and/or nuclear expression of p63 protein was observed in different proportions of cells. With expression of p63 in tumor cells, relapse-free survival was on average 25.7±5.1 months, while in patients with no expression of р63 it was 26.1±2.8 months. This parameter did not influence the overall survival of patients which was on average 33.6±2.7 months. Conclusion. A weak tendency to reduction of relapse-free survival of patients with p63-positive pulmonary carcinoma of lungs was revealed. Identification of p63 in pulmonary adenocarcinoma may be regarded as a factor of unfavorable prognosis and of risk of faster tumor progression, which requires further study to increase the statistical value of research.